ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Combining network pharmacology and RNA sequencing to reveal the mechanism of emodin for the treatment of human neuroblastoma.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hederagenin Promotes Sorafenib Sensitivity in Hepatocellular Carcinoma Through Suppressing SLC7A11 Expression and Inducing Ferroptosis.Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Neuroblastoma (NB), as a highly metastatic tumor, represents the most common pediatric extracranial malignancy. Emodin is a natural product extracted from several traditional Chinese medicines, exerting potent anti-cancer properties in various cancer types. However, the detailed mechanism of emodin in the treatment of NB remains unclear. Network pharmacology was employed to explore the mechanism of emodin for the treatment of NB. The cell proliferation markers, cell cycle, cell cycle-related genes, and DNA damage-relevant genes of SH-SY5Y cell were examined by a battery of assays. Animal xenografts were used to evaluate tumor inhibition effect of emodin and perform RNA sequencing. Binding affinity of emodin and essential signaling proteins was investigated using molecular docking and confirmed by western blot analysis. The expression of epithelial-mesenchymal transition markers was also examined by western blot. Network pharmacology uncovered that emodin regulated cell cycle, p53 pathway, and PI3K/AKT pathway in NB. Emodin suppressed the cell proliferation in vitro by inducing the S phase arrest in SH-SY5Y cells, and the animal xenografts confirmed the anti-cancer activity of emodin in vivo. Further RNA-sequencing investigation showed that PI3K/AKT signaling is a potential pathway with emodin treatment. Our results validated that this signaling was indeed suppressed in the emodin-mediated anti-NB process, and molecular docking demonstrated that emodin bound strongly to PI3K and AKT1. And, emodin inhibited the metastasis of SH-SY5Y cells in vitro. Emodin restrained tumor growth by inducing S phase arrest and inhibited metastasis through inhibiting the PI3K/AKT signaling in SH-SY5Y cells.
Indexed as
Identifiers
39945814What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.